Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 10:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: LX4211 Clear all
Completed Phase 1 Interventional

Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus

NCT01188863
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
300 mg LX4211 (150 mg tablets), 300 mg LX4211 (50 mg tablets), 300 mg LX4211 (liquid)
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Sep 17, 2026, 10:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets

NCT02373046
View directory record Official record
Conditions
Healthy
Interventions
LX4211
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Sep 17, 2026, 10:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects

NCT01334242
View directory record Official record
Conditions
Healthy
Interventions
Schedule A, Schedule B, Schedule C, Schedule D, Schedule E
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2011 · Synced Sep 17, 2026, 10:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DDI Study With Multiple-dose LX4211 and Single Dose Digoxin

NCT02300350
View directory record Official record
Conditions
Healthy
Interventions
Treatment A digoxin, Treatment B LX4211, Treatment C Digoxin + 400 mg LX4211 administered concomitantly
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Sep 17, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin

NCT01376557
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
75 mg LX4211, 200 mg LX4211, 400 mg LX4211, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
56
States / cities
Anaheim, California • Carmichael, California • Greenbrae, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Sep 17, 2026, 10:41 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

NCT06481891
View directory record Official record
Conditions
Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 17, 2026, 10:41 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy

NCT02384941
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Placebo, Sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
63
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Sep 17, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C

NCT02383940
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 30 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Tustin, California • Aurora, Colorado • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Sep 17, 2026, 10:41 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone

NCT02531035
View directory record Official record
Conditions
Type 1 Diabetes Mellitus (T1DM), High Level of Sugar (Glucose) in the Blood
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
33
States / cities
Concord, California • Escondido, California • La Jolla, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Sep 17, 2026, 10:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects

NCT01913002
View directory record Official record
Conditions
Healthy
Interventions
LX4211 800 mg, LX4211 2000 mg, moxifloxacin 400 mg, LX4211 Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Sep 17, 2026, 10:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin

NCT02300363
View directory record Official record
Conditions
Healthy
Interventions
Treatment A (rosuvastatin), Treatment B (LX4211), Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly)
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Sep 17, 2026, 10:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects

NCT01292993
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
400 mg LX4211, 1000 mg metformin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Sep 17, 2026, 10:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects

NCT01916863
View directory record Official record
Conditions
Healthy Subjects
Interventions
LX4211 400 mg, canagliflozin 300 mg, LX4211 Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Sep 17, 2026, 10:41 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment

NCT01555008
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Renal Impairment
Interventions
LX4211, LX4211 Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
6
States / cities
Anniston, Alabama • Chula Vista, California • Edgewater, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2013 · Synced Sep 17, 2026, 10:41 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Oral Contraceptive DDI Study

NCT02494609
View directory record Official record
Conditions
Healthy
Interventions
sotagliflozin, oral contraceptive, oral contraceptive + sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
2
States / cities
Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Sep 17, 2026, 10:41 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics

NCT01441232
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
LX4211, Januvia®
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2012 · Synced Sep 17, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus

NCT01742208
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Baton Rouge, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Sep 17, 2026, 10:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects

NCT01916850
View directory record Official record
Conditions
Healthy
Interventions
LX4211 400 mg, LX4211 800 mg, LX4211 Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Sep 17, 2026, 10:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects

NCT01818232
View directory record Official record
Conditions
Healthy
Interventions
[14C]-LX4211
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Sep 17, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

Study of LX4211 in Subjects With Type 2 Diabetes Mellitus

NCT00962065
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
LX4211 Low Dose, LX4211 High Dose, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Sep 17, 2026, 10:41 PM EDT